Last reviewed · How we verify
The midazolam ketamine group
Midazolam is a benzodiazepine that acts as a GABA_A receptor agonist, while ketamine is an NMDA receptor antagonist.
Midazolam is a benzodiazepine that acts as a GABA_A receptor agonist, while ketamine is an NMDA receptor antagonist. Used for Procedural sedation and anesthesia.
At a glance
| Generic name | The midazolam ketamine group |
|---|---|
| Sponsor | Kasr El Aini Hospital |
| Drug class | Benzodiazepine and NMDA receptor antagonist |
| Target | GABA_A receptor, NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | Phase 3 |
Mechanism of action
Midazolam's mechanism of action involves binding to the GABA_A receptor, enhancing the effect of the neurotransmitter gamma-aminobutyric acid (GABA), leading to sedative, hypnotic, anxiolytic, anticonvulsant, and muscle relaxant properties. Ketamine, on the other hand, acts as an antagonist at the NMDA receptor, which is involved in the regulation of synaptic plasticity and memory formation. The combination of midazolam and ketamine may provide synergistic effects in terms of sedation and analgesia.
Approved indications
- Procedural sedation and anesthesia
Common side effects
- Respiratory depression
- Confusion
- Dizziness
Key clinical trials
- Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery (PHASE1)
- The Impact of a Shared Decision-Making Intervention on Intraoperative Patient Experience During Elective Cesarean Delivery Under Spinal Anesthesia (NA)
- Ketamine, SGB and Combination Treatment for TBI (PHASE2)
- Comparative Assessment of Oral Premedication Regimens in Pediatric Ambulatory Surgery (NA)
- Magnesium Sulfate Versus Other Anesthesia Drugs to Reduce Agitation After Adenotonsillectomy in Pediatric Patients (NA)
- Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches (PHASE3)
- Effects of an Opioid Free/Sparing Care Pathway for Patients Undergoing Obesity Surgery (NA)
- Adjuvant Continuous Infusion of Nefopam Versus Standard of Care in Mechanically Ventilated Critically Ill Patients: Randomized Double-blind Controlled Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- The midazolam ketamine group CI brief — competitive landscape report
- The midazolam ketamine group updates RSS · CI watch RSS
- Kasr El Aini Hospital portfolio CI